Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Zimmer Biomet Holdings, Inc. ZBH

Healthcare — Medical Devices
S&P 500 Member Dividend Champion (5y)
Indexes indicate stock being part of an index ,
Growth Flags show if company had growth for consecutive years

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
1.58
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — 1 1 — 1 — — — 2
Insider Ownership
0.94%

Capital & Financial Ratios

Market Cap
17,980.00
Revenue
8,508.80
Net Income
807.00
Free Cash Flow
1,036.50
Net Debt
7,069.00
Current Ratio
1.69
Debt/Equity
0.59
P/E ratio
23.09
P/S ratio
2.15
P/B ratio
1.45
Past 5Y EPS Growth
(4.13%)
This Y EPS Growth
4.05%
Next Y EPS Growth
6.28%
Next 5Y EPS Growth
5.85%
in millions of $

Dividends

Payout Ratio
0.40
Annual Dividend Rate
0.96
Annual Dividend Yield
0.69%
total individual payouts
2028 ‡‡‡‡‡
2027 ‡‡‡‡‡
2026 0.99
—
—
—
2025 0.96
—
—
—
—
2024 0.96
—
—
—
—
2023 0.96
—
—
—
—
2022 0.96
—
—
—
—
2021 0.93
—
—
—
—
2020 0.93
—
—
—
—
2019 0.93
—
—
—
—
2018 0.93
—
—
—
—
2017 0.93
—
—
—
—
2016 0.93
—
—
—
—
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 415.80 525.50 591.90 410.00
Receivables 1,442.40 1,480.70 1,704.40 1,769.50
Inventory 2,385.20 2,235.30 2,286.40 2,270.30
Other 366.10 430.10 537.30 646.90
4,609.50 4,671.50 5,119.90 5,096.70
2023 2024 2025 Q'26
Payables 410.60 194.60 303.00 352.40
ST’ Debt 900.00 863.00 587.10 1,201.50
Other 1,546.90 1,393.30 1,693.60 1,125.30
2,857.40 2,450.90 2,583.70 3,013.50
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 2,086.70 2,177.00 — —
—
’25 1,909.10 2,077.30 2,001.40 2,243.70
8,231.50
’24 1,889.20 1,942.00 1,824.20 2,023.20
7,678.60
’23 1,831.00 1,869.60 1,753.60 1,940.00
7,394.20
’22 1,663.20 1,781.80 1,669.80 1,825.10
6,939.90
’21 1,601.40 1,763.30 1,685.40 1,777.20
6,827.30
’20 1,783.80 1,226.10 1,929.30 1,188.30
6,127.50
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 359.40 447.80 — —
—
’25 382.80 378.20 418.70 517.40
1,697.10
’24 228.00 369.40 395.70 506.30
1,499.40
’23 307.70 347.90 337.60 588.40
1,581.60
’22 315.70 345.50 450.80 244.20
1,356.20
’21 223.50 419.00 424.20 337.60
1,404.30
’20 450.90 (52.80) 381.30 296.20
1,075.60
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 206.90 246.00 — —
—
’25 276.10 217.60 267.70 315.90
1,119.70
’24 47.60 197.50 287.70 249.90
902.30
’23 164.20 112.80 156.70 441.70
875.40
’22 222.90 240.40 332.00 85.00
880.30
’21 125.50 333.30 310.50 209.40
978.70
’20 325.00 (145.40) 287.20 237.50
704.30
in millions of $

EPS

Mar Jun Sep Dec Year
’26 1.22 1.03 — —
—
’25 0.91 0.77 1.16 0.70
3.55
’24 0.84 1.18 1.23 1.20
4.43
’23 1.11 1.00 0.77 2.01
4.88
’22 0.07 0.73 0.92 (0.62)
1.10
’21 0.94 0.67 0.69 (0.40)
1.91
’20 (2.46) (1.00) 1.16 1.59
(0.67)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

2.5
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ 100.39 102.00 101.47 85.33 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 135.05 149.25 133.90 114.44 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 18,000 18,000 17,000 17,000 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.39 0.41 0.45 0.48 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6,939.90 7,394.20 7,678.60 8,231.50 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 70.90% 71.82% 71.46% 69.71% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 403.50 1,067.30 1,036.60 830.80 — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.81% 14.43% 13.50% 10.09% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 291.20 1,025.10 905.20 705.10 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,219.20 951.70 996.30 1,093.80 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 33.11 35.43 37.81 41.57 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ 1.10 4.91 4.45 3.56 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.47 7.58 7.38 8.57 — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.27) (3.38) (2.94) (2.92) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.20 4.19 4.44 5.66 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 57.38 59.84 61.43 64.17 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 209.60 208.70 203.10 198.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ 115.71 24.72 23.74 25.19 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.84 3.43 2.79 2.16 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.22 2.03 1.72 1.40 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.61 4.15 3.53 3.00 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 36.70 35.05 34.67 22.96 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,356.20 1,581.60 1,499.40 1,697.10 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (475.90) (706.20) (597.10) (577.40) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 880.30 875.40 902.30 1,119.70 — — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2,069.10 1,752.10 2,220.60 2,536.20 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5,696.50 5,767.90 6,204.60 7,519.10 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5,320.80 5,352.10 5,679.10 6,927.20 — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 12,027.00 12,488.10 12,476.20 12,705.80 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.04% 4.81% 4.22% 3.17% — — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.51% 4.48% 4.43% 3.50% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.87% 8.35% 7.24% 5.60% — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Zimmer Biomet Holdings (ZBH) showcases resilient revenue recovery in orthopedics, rebounding from a 23% COVID-induced plunge in 2020 to 14% YoY growth by 2023, with efficiency gains driving revenue per employee up 9% to $452k in 2024 amid a 15% workforce cut. Projections signal a modest 5-7% CAGR through 2027 to $8.85B, fueled by robotics like ROSA and aging demographics, yet tempered by competition and reimbursement headwinds. However, profitability volatility persists—EBT margins eased to 13.5% in 2024 after a 164% surge in 2023—while debt climbs 21% to $7.52B in 2025, pressuring ROIC at 4.4% and ROE at 7.2%.

Valuation reflects caution: multiples compressed to 23.7x PE and 2.8x PS, with stock highs flat at ~$134 despite 11% revenue growth since 2022, trading near consensus targets (4% upside, 9% downside risk). Zero insider buys and $750k+ in sells signal restraint, alongside risks from Medicare cuts and supply inflation. A hold stance prevails, backed by steady FCF/share at ~$5.66 projected for 2025, but Q1 2026 procedure volumes will test the trajectory—inviting scrutiny for conservative portfolios.

Read full commentary →

Zimmer Biomet Holdings, Inc. (ZBH) Latest News

News by impact score

Fine-tune

18 Sep

3 www.trefis.com, 8:33 AM
Intuitive Surgical considers lowering price per surgery while seeking to offset revenue impact via higher procedure volumes or cost efficiencies, potentially heightening competition for Zimmer Biomet's ROSA robotic systems in orthopedics. Pricing pressure from Intuitive Surgical may modestly affect Zimmer Biomet's robotic-assisted surgery adoption and margins but is unlikely to reshape overall trajectory.

14 Sep

3 , 10:11 AM
Zimmer Biomet Holdings adopted a new leadership structure for its Americas and robotics units, altering the company's investment narrative. Americas and robotics leadership changes at Zimmer Biomet affect operational focus and competitive positioning without fundamentally shifting long-term trajectory.

3 www.medtechdive.com, 6:00 AM
Zimmer Biomet Holdings, Inc. proposes cutting 580 jobs in Switzerland. Workforce reduction of 580 positions signals operational restructuring with moderate effects on costs and efficiency.

14 Aug

3 , 5:49 AM
Zimmer Biomet's Q2 earnings call drew analyst questions on revenue trends, orthopedic product demand, robotics strategy, and margin pressures in the medical device market. Earnings call analyst questions highlight operational and market issues that can moderately sway investor views on near-term performance.

13 Aug

3 , 1:49 PM
Stryker posts Q2 recovery with guidance pointing to stronger second-half results, highlighting momentum in orthopedics that may influence peer performance including Zimmer Biomet. Stryker's recovery sets competitive benchmark that can shift market sentiment and positioning for Zimmer Biomet.

12 Aug

4 transcript www.fool.com, 10:00 AM
Zimmer Biomet Holdings, Inc. (ZBH) released its Q2 2026 earnings call transcript covering financial results, operational updates, and forward guidance. Q2 2026 earnings results and management commentary can significantly affect stock price and market perception.

9 Aug

4 transcript www.marketbeat.com, 2:03 PM
Zimmer Biomet Holdings reported Q2 earnings results and operational highlights during its earnings call. Q2 earnings call reveals critical financial metrics and strategic updates affecting investor decisions.

7 Aug

3 , 1:15 AM
Zimmer Biomet Holdings beat earnings expectations and raised guidance, leading to questions on whether its valuation now aligns with performance. Earnings beat and raised guidance moderately boost financial outlook and investor sentiment without fundamentally reshaping company trajectory.

6 Aug

3 www.medtechdive.com, 6:13 AM
Zimmer Biomet CEO reports sales force revamp progressing better than expected. Sales force optimization can lift revenue execution and sentiment but amounts to incremental operational tuning.

5 Aug

4 transcript , 5:05 PM
Zimmer Biomet Holdings Inc reported strong sales beat during its Q2 2026 earnings call. Strong sales beat signals positive financial momentum likely boosting stock performance and future outlook.

4 www.medicaldevice-network.com, 12:15 PM
Zimmer Biomet Holdings reported 4.8% year-over-year revenue growth in Q2 and raised its 2026 outlook. Q2 revenue increase and raised 2026 guidance point to stronger financial trajectory and investor confidence.

4 investorshub.advfn.com, 8:57 AM
Zimmer Biomet Holdings raised its full-year outlook after beating second-quarter earnings. Earnings beat and raised full-year outlook indicate stronger results and prospects that can shift investor sentiment and stock trajectory.

3 transcript app.moby.co, 5:01 PM
Zimmer Biomet Holdings, Inc. issued Q2 2026 earnings call summary covering quarterly financial results and outlook. Quarterly earnings updates influence near-term financial expectations and market sentiment without major strategic shifts.

3 , 11:47 AM
ZBH beat Q2 earnings expectations, raised its 2026 outlook, and its stock rose in pre-market trading. Earnings beat combined with raised 2026 guidance can lift near-term investor sentiment and share price.

3 , 7:45 AM
Zimmer Biomet Holdings, Inc. (ZBH) reported Q2 earnings and revenues that beat analyst estimates. Q2 earnings and revenue beat delivers moderate positive short-term boost to stock and sentiment without major strategic shift.

3 , 6:53 AM
Zimmer Biomet Holdings beat Q2 CY2026 revenue expectations. Q2 revenue beat signals positive financial performance without altering long-term trajectory.

3 , 6:30 AM
Zimmer Biomet Holdings reported second quarter 2026 financial results. Quarterly earnings releases typically produce moderate short-term stock movement without altering long-term strategy.

29 Jul

3 , 5:09 PM
Zimmer Biomet (ZBH) shares rise 7.7% after first-quarter earnings beat and confident outlook commentary. Q1 beat and positive outlook improve near-term sentiment and operational visibility for Zimmer Biomet.

3 , 8:58 AM
Zimmer Biomet Holdings is scheduled to report Q2 earnings with focus on expected results and influencing factors. Preview of quarterly earnings can shift near-term sentiment and trading without altering long-term company trajectory.

27 Jul

3 , 9:33 PM
Zimmer Biomet reports Q1 earnings in surgical equipment and consumables, earning top marks amid diversified results. Q1 results with top marks support moderate gains in financial performance and positioning.

22 Jul

3 www.barchart.com, 11:04 AM
Zimmer Biomet Holdings, Inc. (ZBH) is scheduled to release its quarterly earnings, with focus on expected revenue, EPS figures, year-over-year comparisons, and any updated forward guidance that could shape near-term investor views. Earnings previews set expectations that can moderately sway short-term stock movement and sentiment ahead of the actual release.

20 Jul

3 www.trefis.com, 3:15 PM
Zimmer Biomet faces a paradox in its robotics segment where heavy investments in systems like ROSA yield limited near-term returns amid high costs and slow adoption, pressuring margins despite long-term orthopedic market potential. Robotics investment dynamics may moderately shift ZBH innovation pace and margins without fundamentally redefining overall trajectory.

2 Jul

4 , 12:29 AM
Zimmer Biomet acquires Pacira's Iovera device and expands into spasticity treatment. Acquisition expands ZBH product portfolio into spasticity with new device and market entry.

1 Jul

4 www.medicaldevice-network.com, 6:53 AM
Zimmer Biomet Holdings acquires iovera device from Pacira for $140m. Acquisition expands Zimmer Biomet product portfolio via $140m purchase of iovera device.

3 , 9:30 AM
Zimmer Biomet acquires Pacira's iovera business in a deal worth up to $140 million. Acquisition adds iovera technology to Zimmer Biomet portfolio with moderate effect on product positioning.

30 Jun

3 , 7:30 AM
Zimmer Biomet acquires Pacira BioSciences' iovera° business via divestiture agreement. Acquisition adds cryoneurolysis technology to Zimmer Biomet portfolio with moderate effects on operations and positioning.

3 www.medtechdive.com, 7:17 AM
Zimmer Biomet Holdings to acquire Pacira pain relief device for up to $140 million. Acquisition expands Zimmer product portfolio in pain management with modest revenue upside.

9 Jun

3 Zacks, 10:01 AM
GMED is leveraging strategic initiatives to capture growth in the expanding musculoskeletal market, enhancing its competitive stance against peers like Zimmer Biomet. GMED advancing in the shared musculoskeletal space creates moderate competitive pressure on Zimmer Biomet's market position.

15 May

4 Simply Wall St., 12:37 AM
Zimmer Biomet Holdings, Inc. (ZBH) announced an expanded US$1 billion share repurchase plan, prompting a valuation review amid positive market signals. Expanded $1B share repurchase demonstrates strong cash flow confidence and boosts EPS, significantly enhancing investor sentiment and stock trajectory.

3 StockStory, 11:00 PM
Zimmer Biomet Holdings shares rise after the company posts stronger-than-expected quarterly results and raises full-year revenue and earnings guidance, driven by higher orthopedic procedure volumes and improved pricing. Earnings beat and raised guidance provide a short-term lift to financial outlook and sentiment but do not signal major strategic or competitive shifts.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us